In particularly, recent advances have demonstrated JNK pathway as a potential target for IBD therapy, the beneficial effects of JNK inhibitors in reducing intestinal inflammation are currently under exclusive investigations, whether the JNK isoform and its inhibitors converge intestinal barrier function to regulate pathological process in CD is largely unknown. The gene discussed is MAPK8; the disease is inflammatory bowel disease.